Therapy News and Research

RSS

Schering-Plough provides update on phase II study of Vicriviroc

Schering-Plough Corporation has provided an update on vicriviroc, its investigational CCR5 receptor antagonist, currently being evaluated by the NIH-sponsored Adult AIDS Clinical Trials Group (ACTG) in an ongoing Phase II clinical study of 118 U.S. treatment-experienced HIV patients.

6 Mar 2006

Orthopaedic medical device technologies that offer greater clinical benefits expected to succeed

Current users of medical device technologies for orthopaedic applications seek systems that offer maximum comfort while requiring minimum physical supervision. This is driving the market to continuously evolve technologies that use radically different approaches or make significant improvements to existing products.

6 Mar 2006

FDA gives greenlight for new treatment of head and neck cancer

The U.S. Food and Drug Administration has approved colon cancer drug Erbitux to treat head and neck cancer after results of a large clinical trial showed the drug prolonged survival by 20 months.

5 Mar 2006

Cannabis destroys cancer cells

Researchers investigating the role of cannabis in cancer therapy reveal it has the potential to destroy leukaemia cells, in a paper published in the March 2006 edition of Letters in Drug Design & Discovery.

1 Mar 2006

Attaching new cytokine to neural stem cells derived from bone marrow kills brain tumor cells

Attaching a recently discovered cytokine to neural stem cells derived from bone marrow, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute have developed a tool to track and kill malignant brain tumor cells and provide long-term protection against their return.

1 Mar 2006

Achieving rapid door-to-balloon times: How top hospitals improve complex clinical systems

Some of the key elements for success in the rapid treatment of heart attacks have been identified by researchers at Yale School of Medicine in a recent issue of Circulation: Journal of the American Heart Association.

1 Mar 2006

The incidence, distribution, and control of tuberculosis

A reduction in tuberculosis (TB) incidence, prevalence and death rate can be achieved by 2015 in most parts of the world, with the greatest challenges occurring in Africa and Eastern Europe, according to a projection by the Stop TB Department of the World Health Organization.

1 Mar 2006

Fibulins inhibit both tumor growth and blood-vessel formation

Researchers at National Jewish Medical and Research Center report in the March issue of Cancer Research that a pair of promising proteins, known as fibulins 3 and 5, slow the growth of cancer tumors in mice by preventing blood vessels from sprouting. The proteins are promising candidates for use in cancer therapy.

1 Mar 2006

Bone marrow stem cells do not improve cardiac function in heart attack patients

There has been increasing evidence that stem cells contribute to regeneration of cardiac tissue and the development of new blood vessels following a heart attack, thus opening up new prospects for stem-cell based therapies.

1 Mar 2006

New method for examining how radiation damages body tissue

The knowledge may make it possible to reduce side effects for cancer patients or to develop treatments for radiation exposure.

1 Mar 2006

Obese people may be more sensitive to pain

The obese patients showed a greater physical response to the electrical stimulation than did the non-obese people, both before and after the training session. This indicates they had a lower tolerance for the painful stimulation despite reporting, in questionnaires, that they felt no more pain than non-obese people.

1 Mar 2006

Amifostine makes radiation more effective

Doctors in Brazil have concluded that the drug amifostine eases many of the most common side effects associated with patients receiving radiation therapy to treat their cancer while simultaneously making the cancer more susceptible to radiation.

1 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006

Ancient DNA helps unearth potential hemophilia therapy

A cut can be life-threatening for people with hemophilia, whose bodies don't produce enough of a protein that prevents prolonged bleeding.

1 Mar 2006

Ethnicity the most important personal characteristic in predicting complementary medicine use

A survey of older adults in rural North Carolina shows that they widely use complementary medicine therapies, but tend to focus on folk or home remedies, such as taking a daily "tonic" of vinegar or using Epsom salts.

1 Mar 2006

HAART is very cost-effective

New research shows that highly active antiretroviral therapy (HAART) is very cost-effective, despite the high price tag. However, the study also shows that reimbursement to physicians treating patients with HIV is critically low, threatening patients' access to care.

1 Mar 2006

Enhanced external counterpulsation (EECP) reduces angina

Patients with angina (chest pain) and left ventricular dysfunction respond very well to treatment using enhanced external counterpulsation (EECP), with little or no future heart failure events, according to researchers from the Cardiovascular Institute at the University of Pittsburgh Medical Center (UPMC).

1 Mar 2006

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer

A new study shows that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI) - the administration of chemotherapy directly to the liver through a pump in the abdomen - fare better than those who received traditional, intravenous chemotherapy.

1 Mar 2006

$Hormone therapy for advanced prostate cancer can lead to bone loss and fractures$

Hormone therapy for advanced prostate cancer can lead to bone loss and fractures

A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.

1 Mar 2006

Can stem cell research lead the way to affordability?

The proliferation of patents in the emerging stem cell field may impede scientists from developing new treatments, says Merrill Goozner of the Center for Science in the Public Interest in the open access journal PLoS Medicine.

1 Mar 2006